EMD-76385

Single-particle
3.43 Å
EMD-76385
3D View Gallery
Deposition: 31/03/2026
Map released: 12/08/2026
Last modified: 12/08/2026
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-76385

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-12es summary report (pdf.gz) Map-12es FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

Cryo-EM structure of BCMA in complex with the BCMA-targeted Fab arm of linvoseltamab and the Fab fragment of an anti-kappa light chain antibody REGN654

EMD-76385

Single-particle
3.43 Å
EMD-76385
3D View Gallery
Deposition: 31/03/2026
Map released: 12/08/2026
Last modified: 12/08/2026
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens, Mus musculus
Sample: BCMA extracellular domain in complex with the BCMA-targeted Fab arm of linvoseltamab and the Fab fragment of an anti-kappa light chain antibody REGN654
Fitted models: 12es

Deposition Authors: Zhou Y, Franklin MC
DISTINCT EPITOPE ENGAGEMENT CONFERS DIFFERENTIAL ACTIVITY OF LINVOSELTAMAB VERSUS TECLISTAMAB ACROSS BCMA MUTATIONS.
Zhou Y, Sineshchekova O, Lee K, Doshi A, Brown K, Franklin MC, Ullman E, Hermann A, Kroog GS, Boyapati A, Smith E, Lin JC, Olson WC, Olson K
(2026) Blood Adv
PUBMED: 42509021
DOI: doi:10.1182/bloodadvances.2026020381
ISSN: 2473-9537
Grant Support: